The treatment of relapsed/refractory multiple myeloma dramatically changed in recent years with the emergence of therapies ...

Multiple myeloma remains an incurable blood cancer, with nearly all patients relapsing and requiring subsequent therapy ...

Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep® ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep (R) (belantamab mafodotin) -- a critical new ...

The combination of talquetamab (Talvey) and daratumumab (Darzalex) demonstrated promising and robust clinical activity for ...

Heidelberg Pharma has reported encouraging progress in its phase 2/2a trial of HDP-101 (INN: pamlectabart tismanitin), its ...

Venetoclax improved PFS but not OS in relapsed/refractory multiple myeloma, with significant benefits in t(11;14) and/or BCL2high subgroups. The overall response rate was higher with venetoclax, and ...

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...